RNAi Therapeutics News and Research

RSS
RNA interference (RNAi) was discovered less than a decade ago and already there are human clinical trials in progress or planned. A major advantage of RNAi versus other anti-sense based approaches for therapeutic applications is that it utilizes cellular machinery that efficiently allows targeting of complementary transcripts, often resulting in highly potent down-regulation of gene expression.
miRagen, Silence partner to assess delivery potential of novel miRNA-based therapeutics

miRagen, Silence partner to assess delivery potential of novel miRNA-based therapeutics

Silence completes siRNA research work with AstraZeneca, MedImmune

Silence completes siRNA research work with AstraZeneca, MedImmune

Alnylam files CTA with the U.K. MHRA to initiate ALN-TTR02 Phase I trial in ATTR

Alnylam files CTA with the U.K. MHRA to initiate ALN-TTR02 Phase I trial in ATTR

Positive preliminary results from Alnylam's Phase I ALN-PCS trial on severe hypercholesterolemia

Positive preliminary results from Alnylam's Phase I ALN-PCS trial on severe hypercholesterolemia

Enrollment complete in Alnylam's ALN-RSV01 Phase IIb study for RSV infection

Enrollment complete in Alnylam's ALN-RSV01 Phase IIb study for RSV infection

Positive preliminary results from Alnylam's ALN-TTR01 Phase I clinical trial for TTR-mediated amyloidosis

Positive preliminary results from Alnylam's ALN-TTR01 Phase I clinical trial for TTR-mediated amyloidosis

Alnylam announces new data from ALN-TTR01 Phase I trial on TTR-mediated amyloidosis

Alnylam announces new data from ALN-TTR01 Phase I trial on TTR-mediated amyloidosis

Access partners to exploit CobaCyte and CobOral technology for targeted RNAi therapeutic delivery

Access partners to exploit CobaCyte and CobOral technology for targeted RNAi therapeutic delivery

GSK, Alnylam collaborate to apply VaxiRNA technology for influenza vaccine production

GSK, Alnylam collaborate to apply VaxiRNA technology for influenza vaccine production

Arrowhead acquires RNA therapeutics assets from Roche

Arrowhead acquires RNA therapeutics assets from Roche

Mirna, Silence enter agreement to assess delivery systems for novel microRNAs

Mirna, Silence enter agreement to assess delivery systems for novel microRNAs

Third Annual Cape Cod Walk 'n' Roll for FSH Muscular Dystrophy on October 1

Third Annual Cape Cod Walk 'n' Roll for FSH Muscular Dystrophy on October 1

Alnylam commences ALN-PCS Phase I trial in severe hypercholesterolemia

Alnylam commences ALN-PCS Phase I trial in severe hypercholesterolemia

Silence Therapeutics reports revenue of £354,078 for six months ended 30 June 2011

Silence Therapeutics reports revenue of £354,078 for six months ended 30 June 2011

Silence receives U.S. patent entitled, 'Use of Protein Kinase N beta'

Silence receives U.S. patent entitled, 'Use of Protein Kinase N beta'

Polyplus-transfection appoints ten additional biologists and chemists to support multiple pre-clinical studies

Polyplus-transfection appoints ten additional biologists and chemists to support multiple pre-clinical studies

InteRNA, Silence partner to develop novel microRNA therapeutics for cancer

InteRNA, Silence partner to develop novel microRNA therapeutics for cancer

Alnylam second quarter revenue decreases to $20.6 million

Alnylam second quarter revenue decreases to $20.6 million

Positive results from Alnylam's ALN-VSP Phase I trial for liver cancer

Positive results from Alnylam's ALN-VSP Phase I trial for liver cancer

'Core-shell' nanoparticles for effective intracellular delivery of RNAi therapeutics

'Core-shell' nanoparticles for effective intracellular delivery of RNAi therapeutics